- Company
- Hanmi & Celltrion are producing generic COVID tx
- by Chon, Seung-Hyun Jan 25, 2022 05:55am
- Hanmi and Celltrion produce oral COVID-19 treatments developed by MSD and supply them to underdeveloped countries. According to the industry on the 20th, Hanmi and Celltrion have completed a license-in contract with the MPP for the production of generic drugs for Molnupiravir (Lagevrio) treatment for COVID-19. The license contract is based on
- Company
- Sales of SGLT-2 diabetes drugs surpassed 150 billion won
- by Ji Yong Jun Jan 24, 2022 05:56am
- Sales of SGLT-2 inhibitor-based diabetes treatments exceeded 150 billion won for the first time last year. The SGLT-2 inhibitor market, including Forxiga and Jardiance, continues to grow at double digits every year. ◆ Sales of SGLT-2 inhibitors have increased five times in the past five years According to UBIST, a pharmaceutic
- Two points to note in Kymriah’s reimbursement process
- by Eo, Yun-Ho Jan 24, 2022 05:56am
- The era where a single shot can cure one’s cancer may be imminent, but with a catch: The single-shot would cost &8361;500 million. Novartis’s novel CAR-T therapy ‘Kymriah (tisagenlecleucel)’ cleared all the steps necessary for reimbursement under the Health Insurance Review and Assessment Service by receiving approval on its adequac
- Company
- BI-Boryung concludes copromotion deal for NOAC ‘Pradaxa’
- by Kim, Jin-Gu Jan 24, 2022 05:56am
- Boehringer Ingelheim and Boryung Pharmaceuticals have concluded its co-promotion deal for Boehringer Ingelheim’s non-vitamin K antagonist oral anticoagulant (NOAC) therapy ‘Pradaxa (dabigatran).’ Boehringer Ingelheim plans to directly sell Pradaxa starting this year. According to industry sources on the 21st, Boehringer Ingelheim an
- Company
- The growth rate of the DPP-4i market increased slightly
- by Ji Yong Jun Jan 24, 2022 05:55am
- The domestic DPP-4i diabetes treatment market, which is formed at 600 billion won a year, slowed down last year. It recorded the lowest growth rate in the last seven years. In the DPP-4 inhibitor market, where growth has slowed, the position of domestic companies has also expanded significantly. Rx sales for foreign company products fell.
- Policy
- Xeloda in breast cancer patients is also reimbursed
- by Lee, Hye-Kyung Jan 24, 2022 05:55am
- The stage and target of administration of Roche Korea's breast cancer treatment Xeloda (Capecitabine) and Korean Pfizer's acute lymphocyte leukemia treatment Besponsa (Inotuzumab Ozogamicin) will be changed. With the establishment of a new chemotherapy benefit standard that has deleted the classification of anticancer drugs in the first and s
- Policy
- Improve the reimb system to accommodate high-priced drugs
- by Lee, Hye-Kyung Jan 21, 2022 05:56am
- The government expressed its will to reform the reimbursement management system with the emergence of super-expensive new drugs. At the ‘Forum for the reimbursement management of high-priced pharmaceuticals,’ Yoon Seok Yang, Director of Ministry of Health and Welfare’s Division of Pharmaceutical Benefits, said, “Concern is what I first fe
- Company
- Avastin biosimilar "Onbevezy" can be prescribed in earnest
- by Eo, Yun-Ho Jan 21, 2022 05:56am
- Samsung Bioepis' Avastin biosimilar Onbevezy has become possible to be prescribed in earnest. According to related industries, Onbevezy, a biosimilar of the blockbuster anticancer drug Avastin, passed DC of medical institutions such as Chilgok Kyungpook National University Hospital and Hwasun Chonnam National University Hospital, includin
- Policy
- Alvogen targets the Korean market with a Spanish biosimilar
- by Lee, Tak-Sun Jan 21, 2022 05:56am
- Alvogen’s Korea is attempting to target the domestic anticancer drug market with a Spanish biosimilar. Its product is the third Avastin (bevacizumab) biosimilar to enter the market after Samsung Bioepis and Pfizer. On whether the new biosimilar will become a new sensation among latecomers in the market and is gaining attention. On the 19
- Policy
- Pt management is required to provide high priced 1 shot tx
- by Lee, Hye-Kyung Jan 21, 2022 05:56am
- Starting with Kymriah of Novartis Korea, which recently passed the HIRA Drug Reimbursement Evaluation Committee, the search for management measures for ultra-high-priced one-shot treatments has begun with Zolgensma, which is expected to enter Korea. In the end, the government's plan to manage the benefits of expensive drugs is a contract that
